OverviewSuggest Edit

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. The Company leverages the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Aptevo’s ADAPTIR technology is suitable for producing immunotherapeutics for oncology, hematology, and autoimmune and inflammatory diseases.

TypePublic
Founded2016
HQSeattle, WA, US
Websiteaptevotherapeutics.com
Employee Ratings4.5

Latest Updates

Employees (est.) (Dec 2018)118(-2%)
Job Openings5
Revenue (FY, 2020)$4.3 M(-86%)
Share Price (Nov 2021)$11.6(-8%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Aptevo Therapeutics

Marvin L. White

Marvin L. White

President, Chief Executive Officer & Director
Jeff Lamothe

Jeff Lamothe

SVP and Chief Financial Officer
Scott C. Stromatt

Scott C. Stromatt

Chief Medical Officer
Randy J. Maddux

Randy J. Maddux

SVP and Chief Manufacturing Officer
Show more

Aptevo Therapeutics Office Locations

Aptevo Therapeutics has an office in Seattle
Seattle, WA, US (HQ)
2401 4th Ave #1050
Show all (1)

Aptevo Therapeutics Financials and Metrics

Aptevo Therapeutics Revenue

Aptevo Therapeutics's revenue was reported to be $4.31 m in FY, 2020
USD

Revenue (Q1, 2021)

2.4m

Net income (Q1, 2021)

(7.3m)

EBIT (Q1, 2021)

(6.9m)

Market capitalization (12-Nov-2021)

62.4m

Closing stock price (12-Nov-2021)

11.6

Cash (31-Mar-2021)

57.5m

EV

21.8m
Aptevo Therapeutics's current market capitalization is $62.4 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

36.4m14.7m23.1m32.4m4.3m

Revenue growth, %

(60%)57%

Cost of goods sold

24.2m5.0m11.2m19.9m

Gross profit

12.3m9.6m11.9m12.5m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

10.2m9.4m7.4m10.8m6.2m4.1m6.8m5.8m7.4m9.0m473.0k2.4m

Cost of goods sold

6.5m6.2m488.0k5.9m1.9m1.8m2.5m2.4m3.8m6.0m4.0m

Gross profit

3.6m3.2m6.9m4.9m4.3m2.3m4.3m3.4m1.4m5.1m

Gross profit Margin, %

36%34%93%45%70%56%63%58%19%56%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

9.7m7.1m30.6m12.4m40.0m

Accounts Receivable

4.3m2.1m5.2m7.0m

Prepaid Expenses

5.6m6.7m6.9m4.2m2.2m

Inventories

6.6m1.0m1.8m6.1m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

5.5m10.9m14.0m22.3m75.8m11.8m7.2m28.4m37.0m21.0m17.7m12.3m7.6m57.5m

Accounts Receivable

8.5m3.0m1.9m4.7m528.0k3.1m6.1m6.2m5.8m7.4m7.9m

Prepaid Expenses

3.9m3.8m6.1m5.9m6.4m4.1m4.9m5.2m6.9m5.2m2.2m1.3m641.0k1.6m

Inventories

20.1m11.6m8.1m8.0m1.2m1.3m3.0m4.0m4.3m7.0m7.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(112.4m)7.0m(53.7m)(40.4m)(17.7m)

Depreciation and Amortization

3.4m3.1m2.4m2.2m1.4m

Inventories

13.7m(567.0k)(757.0k)(4.4m)

Accounts Payable

2.5m195.0k1.3m938.0k(702.0k)
USDQ2, 2016

Financial Leverage

1.2 x
Show all financial metrics

Aptevo Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

71/100

SecurityScorecard logo

Aptevo Therapeutics Online and Social Media Presence

Embed Graph

Aptevo Therapeutics News and Updates

Thinking about buying stock in Aptevo Therapeutics, Navitas Semiconductor, Berkshire Grey, Aadi Bioscience, or Emergent Biosolutions?

NEW YORK, Nov. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APVO, NVTS, BGRY, AADI, and EBS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit

SEATTLE and LUND, Sweden, June 10, 2020 /PRNewswire/ -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, and Alligator Bioscience AB (Nasdaq...

Aptevo Therapeutics Reports Third Quarter 2019 Financial Results

Reports Record Net Revenue for IXINITY; Achieves 55% Increase in Year-over-Year Quarterly Net Revenue

Aptevo Therapeutics Reports Second Quarter 2019 Financial Results

Reports Positive Preliminary Top-Line Safety Data for APVO210Phase 1 Single Ascending Dose (SAD) Clinical Study

Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials

Completes Dosing in Single Ascending Dose (SAD) Phase 1 Study of APVO210

Aptevo Therapeutics Reports First Quarter 2019 Financial Results

Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY® Net Revenue
Show more

Aptevo Therapeutics Blogs

Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia

SEATTLE, WA / ACCESSWIRE / November 23, 2021 /   Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today

Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting

Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting Content Import Mon, 11/15/2021 - 08:09 Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting…

Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights

Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights Content Import Fri, 11/12/2021 - 08:06 Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights 11/12/21 This release is a backfill from a News Wir…

Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021

Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021 Content Import Thu, 11/11/2021 - 16:45 Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021 …

Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting

Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting Content Import Thu, 11/11/2021 - 08:32 Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cance…

Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021

SEATTLE, WA / ACCESSWIRE / October 27, 2021 /   Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, will
Show more

Aptevo Therapeutics Frequently Asked Questions

  • When was Aptevo Therapeutics founded?

    Aptevo Therapeutics was founded in 2016.

  • Who are Aptevo Therapeutics key executives?

    Aptevo Therapeutics's key executives are Marvin L. White, Jeff Lamothe and Scott C. Stromatt.

  • How many employees does Aptevo Therapeutics have?

    Aptevo Therapeutics has 118 employees.

  • What is Aptevo Therapeutics revenue?

    Latest Aptevo Therapeutics annual revenue is $4.3 m.

  • What is Aptevo Therapeutics revenue per employee?

    Latest Aptevo Therapeutics revenue per employee is $36.5 k.

  • Who are Aptevo Therapeutics competitors?

    Competitors of Aptevo Therapeutics include Totient, Sentinel Oncology and Pangaea Oncology.

  • Where is Aptevo Therapeutics headquarters?

    Aptevo Therapeutics headquarters is located at 2401 4th Ave #1050, Seattle.

  • Where are Aptevo Therapeutics offices?

    Aptevo Therapeutics has an office in Seattle.

  • How many offices does Aptevo Therapeutics have?

    Aptevo Therapeutics has 1 office.